A validated LC–MS/MS method for the determination of specnuezhenide and salidroside in rat plasma and its application to a pharmacokinetic study. (16th August 2018)

• Record Type: Journal Article
• Authors: Ding, Yan; Ju, Zhengcai; Ma, Chao
• Is Part Of: Biomedical chromatography. Volume 32:Number 12(2018)
• Page Start: n/a
• Page End: n/a
• Publication Date: 2018-08-16
• Subjects: bioavailability -- pharmacokinetic -- salidroside -- specnuezhenide; Chromatographic analysis -- Periodicals; Biology -- Periodicals; Medicine -- Periodicals; Biology -- Periodicals; Chromatography -- methods -- Periodicals; Medicine -- Periodicals; 543.089
• DOI: 10.1002/bmc.4353
• Languages: English
• ISSNs: 0269-3879

Abstract

Abstract: The aim of this study was to establish and validate a rapid and sensitive LC–MS/MS method for the simultaneous determination of specnuezhenide and its bioactive metabolite salidroside in rat plasma. Protein precipitation was carried out and the analytes were separated on a Waters Acquity UPLC HSS T3 column (2.1 × 100 mm, 1.8 μm). A mobile phase consisting of acetonitrile and 0.1% formic acid aqueous solution was used for elution under gradient conditions at a flow rate of 0.4 mL/min. Quantification was performed in the negative multiple reaction monitoring mode with precursor‐to‐product transitions at m / z 685.2 → 453.1 for specnuezhenide, m / z 229.3 → 119.0 for salidroside and 493.2 → 147.1 for the internal standard. The method showed good linearity, accuracy, precision and stability in the range 0.5–500.0 ng/mL for specnuezhenide and salidroside. The values of the matrix effect were within the range of 100.02–111.87% for both analytes, while the mean extraction recovery was within the range 64.19–78.26%. The intra‐ and inter‐day precisions (RSD) were <13.49% and the accuracy (RR) ranged from 93.59 to 102.24%. This study was successfully utilized for the pharmacokinetic study of specnuezhenide in rats after oral and intravenous administration. The oral bioavailability of specnuezhenide was 1.93%.